Skip to main content
. 2008 Jul 14;52(9):3237–3243. doi: 10.1128/AAC.00133-08

FIG. 2.

FIG. 2.

Percentages of patient responders at month 3 (M3) as a function of the number of mutations for the TPV mutation score developed by Boehringer Ingelheim (10V, 13V, 20 M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, and 84V).